

1. A crystalline form of (10*R*)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2*H*-8,4-(metheno)pyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (lorlatinib) free base hydrate, having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of: 8.8, 17.6 and $18.8^\circ 2\theta \pm 0.2^\circ 2\theta$.
2. The crystalline form of claim 1, having a PXRD pattern further comprising a peak at the 2θ value of: $9.7^\circ 2\theta \pm 0.2^\circ 2\theta$.
3. The crystalline form of claim 1 or 2, having a PXRD pattern further comprising a peak at the 2θ value of: $10.9^\circ 2\theta \pm 0.2^\circ 2\theta$.
4. The crystalline form of claim 1, 2 or 3, having a ^{13}C solid state NMR spectrum comprising resonance (ppm) values of: 40.2, 41.2 and $136.2 \text{ ppm} \pm 0.2 \text{ ppm}$.
5. The crystalline form of claim 4, having a ^{13}C solid state NMR spectrum further comprising the resonance (ppm) value of: $128.1 \text{ ppm} \pm 0.2 \text{ ppm}$.
6. The crystalline form of claim 4 or 5, having a ^{13}C solid state NMR spectrum further comprising the resonance (ppm) value of: $145.3 \text{ ppm} \pm 0.2 \text{ ppm}$.
7. The crystalline form of any one of claims 1 to 6, having a ^{19}F solid state NMR spectrum comprising a resonance (ppm) value of: $-104.0 \text{ ppm} \pm 0.2 \text{ ppm}$.
8. The crystalline form of lorlatinib free base hydrate according to any one of claims 1 to 7, wherein the crystalline form is substantially pure.
9. A pharmaceutical composition comprising the crystalline form of lorlatinib free base hydrate according to any one of claims 1 to 8, and a pharmaceutically acceptable carrier or excipient.
10. A crystalline form of lorlatinib free base hydrate according to any one of claims 1 to 8, for use in the treatment of cancer in a mammal.

5 11. A crystalline form of lorlatinib free base hydrate for use according to claim 10 wherein the cancer is non-small cell lung cancer (NSCLC), neuroblastoma, anaplastic large cell lymphoma (ALCL) or gastric cancer.

 12. A crystalline form of lorlatinib free base hydrate for use according to claim 11 wherein the cancer is non-small cell lung cancer (NSCLC).